A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

This study has been completed.

First Received: January 3, 2003 Last Updated: August 4, 2008 History of Changes

Sponsor:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00051181

Purpose

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Condition	Intervention	Phase
Glaucoma, Angle-Closure Ocular Hypertension	Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%)	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Latanoprost Travoprost

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date:	January 2000
Study Completion Date:	June 2003
Primary Completion Date:	June 2003 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051181

Locations

United States, Texas
Asia
Fort Worth, Texas, United States
Australia
Australia
Sidney, Australia

Sponsors and Collaborators

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-01-38
Study First Received:	January 3, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00051181 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Glaucoma
POAG
OAG
OHT

Additional relevant MeSH terms:

Eye Diseases
Vascular Diseases
Cardiovascular Agents
Latanoprost
Antihypertensive Agents
Pharmacologic Actions
Travoprost

Glaucoma
Therapeutic Uses
Cardiovascular Diseases
Glaucoma, Angle-Closure
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on November 22, 2009